Literature DB >> 22476980

Natural inhibitors of poly(ADP-ribose) polymerase-1.

Marek Banasik1, Todd Stedeford, Robert P Strosznajder.   

Abstract

Poly(ADP-ribose) polymerases (PARPs) are enzymes that catalyze the transfer of ADP-ribose units from β-nicotinamide adenine dinucleotide (NAD(+)) to acceptor proteins. PARP-1 is responsible for more than 90 % of protein poly-ADP-ribosylation in the brain and may play a role as a molecular switch for cell survival and death. The functional roles of PARP-1 are largely mediated by its activation after binding to damaged DNA. Upon binding, PARP-1 activity increases rapidly and cleaves NAD(+) into ADP-ribose and nicotinamide. Increased activity of PARP-1 can promote DNA repair and its interaction with several transcription factors, whereas hyperactivation of PARP-1 can result in poly(ADP-ribose) accumulation and depletion of NAD(+) and ATP which may lead to caspase independent apoptotic or necrotic cell death, respectively. Excessive PARP-1 activity has been implicated in the pathogenesis of numerous clinical conditions such as stroke, myocardial infarction, inflammation, diabetes, and neurodegenerative disorders. Therefore, it is not surprising that the search for PARP-1 inhibitors with specific therapeutic uses (e.g., brain ischemia, cancer) has been an active area of research. Beyond medicinal uses, naturally occurring PARP-1 inhibitors may also offer a unique preventative means at attenuating chronic inflammatory diseases through dietary supplementation. This possibility has prompted research for specific, naturally occurring inhibitors of PARP-1. Though fewer investigations focus on identifying endogenous inhibitors/modulators of PARP-1 activity in vivo, these activities are very important for better understanding the complex regulation of this enzyme and the potential long-term benefits of supplementation with PARP-1 inhibitors. With this in mind, the focus of this article will be on providing a state-of-the-science review on endogenous and naturally occurring compounds that inhibit PARP-1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476980     DOI: 10.1007/s12035-012-8257-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  93 in total

Review 1.  Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.

Authors:  Tiina M Kauppinen
Journal:  Neurochem Int       Date:  2007-01-12       Impact factor: 3.921

2.  Inhibition of poly(ADP-ribose) polymerase-1 by arsenite interferes with repair of oxidative DNA damage.

Authors:  Wei Ding; Wenlan Liu; Karen L Cooper; Xu-Jun Qin; Patrícia L de Souza Bergo; Laurie G Hudson; Ke Jian Liu
Journal:  J Biol Chem       Date:  2008-12-03       Impact factor: 5.157

3.  Regulation of poly(ADP-ribose) transferase activity by 2',5'-oligoadenylates.

Authors:  A D Pivazian; H Suzuki; A A Vartanian; A M Zhelkovsky; B Farina; E Leone
Journal:  Biochem Int       Date:  1984-08

Review 4.  Poly(ADP-ribosyl)ation regulation of life and death in the nervous system.

Authors:  D W Koh; T M Dawson; V L Dawson
Journal:  Cell Mol Life Sci       Date:  2005-04       Impact factor: 9.261

5.  Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB.

Authors:  Ming Sun; Yumei Zhao; Yi Gu; Chao Xu
Journal:  Amino Acids       Date:  2011-03-16       Impact factor: 3.520

6.  Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats.

Authors:  K Takahashi; J H Greenberg; P Jackson; K Maclin; J Zhang
Journal:  J Cereb Blood Flow Metab       Date:  1997-11       Impact factor: 6.200

7.  Inhibition of ADP-ribosylation of histone H1 by analogs of diadenosine 5',5'''-p1,p4-tetraphosphate.

Authors:  H Suzuki; Y Tanaka; D T Buonamassa; B Farina; E Leone
Journal:  Mol Cell Biochem       Date:  1987-03       Impact factor: 3.396

8.  In vitro effect of 3,5,3'-triiodothyronine on poly(ADP-ribosyl)ation of DNA topoisomerase I.

Authors:  P Giannoni; L Scarabelli; M Orunesu; C F Cesarone
Journal:  Ital J Biochem       Date:  1995 May-Jun

9.  ADP-ribosylation of diadenosine 5',5"-P1,P4-tetraphosphate by poly(ADP-ribose) polymerase in vitro.

Authors:  K Yoshihara; Y Tanaka
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

10.  Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide.

Authors:  Kashyap G Pandya; Maulik R Patel; Cesar A Lau-Cam
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

View more
  11 in total

Review 1.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

2.  Endogeous sulfur dioxide protects against oleic acid-induced acute lung injury in association with inhibition of oxidative stress in rats.

Authors:  Siyao Chen; Saijun Zheng; Zhiwei Liu; Chaoshu Tang; Bin Zhao; Junbao Du; Hongfang Jin
Journal:  Lab Invest       Date:  2015-01-12       Impact factor: 5.662

Review 3.  The NAD+-Dependent Family of Sirtuins in Cerebral Ischemia and Preconditioning.

Authors:  Nathalie Khoury; Kevin B Koronowski; Juan I Young; Miguel A Perez-Pinzon
Journal:  Antioxid Redox Signal       Date:  2017-08-07       Impact factor: 8.401

4.  A versatile strategy for the design and synthesis of novel ADP conjugates and their evaluation as potential poly(ADP-ribose) polymerase 1 inhibitors.

Authors:  Yuliya V Sherstyuk; Alexandra L Zakharenko; Mikhail M Kutuzov; Polina V Chalova; Maria V Sukhanova; Olga I Lavrik; Vladimir N Silnikov; Tatyana V Abramova
Journal:  Mol Divers       Date:  2016-09-27       Impact factor: 2.943

Review 5.  Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.

Authors:  Robert N Mahon; Richard Hafner
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

6.  Alteration of poly(ADP-ribose) metabolism affects murine sperm nuclear architecture by impairing pericentric heterochromatin condensation.

Authors:  Mirella L Meyer-Ficca; Julia D Lonchar; Motomasa Ihara; Jessica J Bader; Ralph G Meyer
Journal:  Chromosoma       Date:  2013-06-01       Impact factor: 4.316

Review 7.  Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress.

Authors:  Csaba Hegedűs; László Virág
Journal:  Redox Biol       Date:  2014-08-21       Impact factor: 11.799

8.  Inhibition of Poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity.

Authors:  Przemysław L Wencel; Walter J Lukiw; Joanna B Strosznajder; Robert Piotr Strosznajder
Journal:  Mol Neurobiol       Date:  2017-07-12       Impact factor: 5.590

9.  Cellular Effects of Butyrate on Vascular Smooth Muscle Cells are Mediated through Disparate Actions on Dual Targets, Histone Deacetylase (HDAC) Activity and PI3K/Akt Signaling Network.

Authors:  Omana P Mathew; Kasturi Ranganna; Joseph Mathew; Meiling Zhu; Zivar Yousefipour; Chelliah Selvam; Shirlette G Milton
Journal:  Int J Mol Sci       Date:  2019-06-14       Impact factor: 5.923

10.  The Sound of Silence: RNAi in Poly (ADP-Ribose) Research.

Authors:  Christian Blenn; Philippe Wyrsch; Felix R Althaus
Journal:  Genes (Basel)       Date:  2012-12-06       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.